Sentences with phrase «translational breast cancer research»

«Black women have been noted to present [at a doctor's office] with later stage cancer, which has a worse outcome — and they don't always get adequate care,» says Ruth ORegan, MD, associate professor of hematology and oncology and director of the translational breast cancer research program at Emory University's Winship Cancer Institute in Atlanta.

She has also obtained a Breast Cancer Research Foundation American Association for Cancer Research (BCRF - AACR) Grant for Translational Breast Cancer Research to explore combined endocrine and ErbB inhibition in ER + / HER2 + breast cancers in 2007, a K23 Career Development Award to explore targeted therapies in breast cancer, and is also co-Leader in three of the four research projects of the NCI - funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE; Carlos Arteaga, Director).

Breast Cancer Research Foundation - AACR Career Development Award for Translational Breast Cancer Research Mary Kay Foundation Innovative Translational Grant Award Department of Defense Breast Research Program Breakthrough Award

Not exact matches

Witt - Enderby is on the grant review panel for the Susan G. Komen Breast Cancer charity, which is placing greater emphasis on translational research, and a corresponding increase in suitable bids.

The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first - of - its - kind study published in the scientific journal PLOS ONE.

This advance in breast cancer research reflects the mission of Stem Cell Reports to provide an open - access forum that communicates basic discoveries in stem cell research as well as translational and clinical studies.

My translational research has focused on trying to find better ways to estimate recurrence risk in patients diagnosed with oestrogen - receptor positive early breast cancer, with the ultimate aim to better personalise our therapies for those patients who have the most to gain from them.

SEATTLE, Feb. 05, 2018 (GLOBE NEWSWIRE)-- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a landmark study in which Danish researchers used the Prosigna ® Breast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andBreast Cancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andCancer Assay risk of recurrence (ROR) score to accurately predict rates of 10 - year distant recurrence (DR) of cancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer in a comprehensive and population - based cohort including all postmenopausal women in Denmark with early - stage hormone receptor (HR)- positive, Her - 2 negative breast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andbreast cancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 andcancer who received 5 years of adjuvant endocrine therapy according to nationwide guidelines between 2000 and 2003.

The system is available in the multi-mode FLEX configuration, which is designed to meet the needs of high - complexity clinical laboratories seeking a single platform with the flexibility to run the Prosigna Breast Cancer Assay and, when operated in the «Life Sciences» mode, process translational research experiments and multiplexed assays developed by the laboratory.

In 1999, Ashworth was appointed the first director of the ICR's Breakthrough Breast Cancer Research Centre, which is now internationally recognized, with more than 120 scientists and researchers working on aspects of the disease ranging from basic molecular and cellular biology through to translational research and clinicalResearch Centre, which is now internationally recognized, with more than 120 scientists and researchers working on aspects of the disease ranging from basic molecular and cellular biology through to translational research and clinicalresearch and clinical trials.

Solid tumors, such as those of breast and ovaries, are the focus of Solid Tumor Translational Research, a network comprised of Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Cancer Care Alliance.

Tags: aspirin, Bezos, bioengineering, Breast Cancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer, Cameron Turtle, Cancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer etiology - prevention - outcomes, CAR t - cell, Clinical Research, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - ViralResearch, Colorectal Cancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral cCancer, genome, hiv, hiv vaccine, hiv vaccine trials network, Human Biology, immunology, Jason Bielas, Lawrence Corey, Matthias Stephan, merkel cell carcinoma, metastasis, Molecular basis of cancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viral ccancer, mylotarg, Obliteride, Paul Nghiem, philanthropy, Polly A Newcomb, Public Health Sciences, RNA, Ruth Etzioni, Soheil Meshinchi, Steven Henikoff, Transplant and Immunotherapy, Tumor specific translational research, Vaccine and Infectious Disease, Vaccine development - Viralresearch, Vaccine and Infectious Disease, Vaccine development - Viral cancers

To identify and stimulate meritorious and fundable basic science - based and translational / clinical research in breast cancer

The Breast SPORE Developmental Research Program provides pilot funding to promote excellent translational research in breast cBreast SPORE Developmental Research Program provides pilot funding to promote excellent translational research in breastResearch Program provides pilot funding to promote excellent translational research in breastresearch in breast cbreast cancer.

The Department of Translational Research hosts 5 technological platforms (Genomics, Protein arrays, High - content screening, Experimental radiotherapy and Preclinical investigation), 4 labeled teams (resistance to therapy in breast cancers, translational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative breTranslational Research hosts 5 technological platforms (Genomics, Protein arrays, High - content screening, Experimental radiotherapy and Preclinical investigation), 4 labeled teams (resistance to therapy in breast cancers, translational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative bretranslational pediatrics, angiogenesis, and immunotherapy) and 3 emergent teams (Circulating biomarkers, uveal melanoma, and new targets in triple negative breast cancers).

Her research interests include both clinical and translational breast cancer - related research.

Washington, DC's only NCI - designated comprehensive cancer center established the Georgetown Lombardi Breast Cancer Patient Advocacy Committee (GLBCPAC) in 2011, a group of breast cancer advocates supporting its basic science, translational and clinical rescancer center established the Georgetown Lombardi Breast Cancer Patient Advocacy Committee (GLBCPAC) in 2011, a group of breast cancer advocates supporting its basic science, translational and clinical resBreast Cancer Patient Advocacy Committee (GLBCPAC) in 2011, a group of breast cancer advocates supporting its basic science, translational and clinical resCancer Patient Advocacy Committee (GLBCPAC) in 2011, a group of breast cancer advocates supporting its basic science, translational and clinical resbreast cancer advocates supporting its basic science, translational and clinical rescancer advocates supporting its basic science, translational and clinical research.

Tags: Andrew Hsieh, Biostatistics and Biomathematics Program, Cancer etiology - prevention - outcomes, Cancer Prevention Program, Cancer Surveillance System, Christopher J Kemp, Good News, Kevin Cheung, Marian Neuhouser, metastatic breast cancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW MeCancer etiology - prevention - outcomes, Cancer Prevention Program, Cancer Surveillance System, Christopher J Kemp, Good News, Kevin Cheung, Marian Neuhouser, metastatic breast cancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW MeCancer Prevention Program, Cancer Surveillance System, Christopher J Kemp, Good News, Kevin Cheung, Marian Neuhouser, metastatic breast cancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW MeCancer Surveillance System, Christopher J Kemp, Good News, Kevin Cheung, Marian Neuhouser, metastatic breast cancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW Mecancer, Peggy Porter, Peter Nelson, Public Health Sciences, Roland Walter, Ruth Etzioni, Sage Bionetworks, SCCA, Seattle Cancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational research, UW MeCancer Care Alliance (SCCA), Seattle Translational Tumor Research, STTR cancer, Tumor specific translational researchTranslational Tumor Research, STTR cancer, Tumor specific translational research, UW Research, STTR cancer, Tumor specific translational research, UW Mecancer, Tumor specific translational researchtranslational research, UW research, UW Medicine

Dr. Carey is a nationally - recognized leader in the field of clinical / translational research in breast cancer, with a particular interest in the clinical implications of different molecular subtypes of breast cancer.